{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:25:18Z","timestamp":1782512718097,"version":"3.54.5"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.clinthera.2009.04.020","type":"journal-article","created":{"date-parts":[[2009,5,14]],"date-time":"2009-05-14T05:11:21Z","timestamp":1242277881000},"page":"692-704","source":"Crossref","is-referenced-by-count":39,"title":["Etravirine: A second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV"],"prefix":"10.1016","volume":"31","author":[{"given":"Daryl S.","family":"Schiller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Youssef-Bessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.04.020_bib1","first-page":"250","article-title":"Pneumocystis pneumonia\u2014Los Angeles","volume":"30","year":"1981","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.1016\/j.clinthera.2009.04.020_bib3","series-title":"New estimates of US HIV prevalence","year":"2006"},{"key":"10.1016\/j.clinthera.2009.04.020_bib4","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJM199803263381310","article-title":"Progress and problems in the fight against AIDS","volume":"338","author":"Hirschel","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2009.04.020_bib5","first-page":"1","article-title":"Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.","year":"2008","journal-title":"US Dept of Health and Human Services"},{"key":"10.1016\/j.clinthera.2009.04.020_bib6","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.300.5.555","article-title":"Antiretroviral treatment of adult HIV infection: 2008 Recommendations of the International AIDS Society-USA panel","volume":"300","author":"Hammer","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2009.04.020_bib7","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1021\/jm040127p","article-title":"From 4,5,6,7-tetrahydro-5-methylimidazo [4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): Fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase","volume":"48","author":"De Corte","year":"2005","journal-title":"J Med Chem."},{"key":"10.1016\/j.clinthera.2009.04.020_bib8","series-title":"Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Pooled 24-week results of DUET-1 and -2: TMC125 (etravirine; ETR) vs placebo in 1203 treatment-experienced HIV-1-infected patients","author":"Cahn","year":"2007"},{"key":"10.1016\/j.clinthera.2009.04.020_bib9","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1126\/science.2418504","article-title":"Characterization of highly immunogenic p66\/p51 as the reverse transcriptase of HTLV-III\/LAV","volume":"231","author":"di Marzo Veronese","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2009.04.020_bib10","doi-asserted-by":"crossref","first-page":"7188","DOI":"10.1073\/pnas.121055998","article-title":"Nonnucleo-side reverse transcriptase inhibitors are chemical enhanc- ers of dimerization of the HIV type 1 reverse transcriptase","volume":"98","author":"Tachedjian","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2009.04.020_bib11","series-title":"Intelence [package insert]","year":"2008"},{"key":"10.1016\/j.clinthera.2009.04.020_bib12","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1021\/jm030558s","volume":"47","author":"Das","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.clinthera.2009.04.020_bib13","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1128\/AAC.48.12.4680-4686.2004","article-title":"TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleo-side reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1","volume":"48","author":"Andries","year":"2004","journal-title":"Antimicrob Agents Chemo- ther"},{"key":"10.1016\/j.clinthera.2009.04.020_bib14","series-title":"Presented at: XVII International HIV Drug Resistance Workshop","article-title":"An update of the list of NNRTI mutations associated with decreased virologic response to etravirine (ETR): Multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data","author":"Vingerhoets","year":"2008"},{"key":"10.1016\/j.clinthera.2009.04.020_bib15","doi-asserted-by":"crossref","first-page":"12773","DOI":"10.1128\/JVI.79.20.12773-12782.2005","article-title":"TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments","volume":"79","author":"Vingerhoets","year":"2005","journal-title":"J Virol."},{"key":"10.1016\/j.clinthera.2009.04.020_bib16","series-title":"Presented at: XVII International AIDS Conference","article-title":"Combined darunavir and etravirine resistance analysis of the pooled DUET trials: When can we spare the other new classes?","author":"Haubrich","year":"2008"},{"key":"10.1016\/j.clinthera.2009.04.020_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)61047-2","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-Week results from a randomized, double-blind, placebo-controlled trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2009.04.020_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(07)61048-4","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-Week results from a randomized, double-blind, placebo-controlled trial","volume":"370","author":"Lazzarin","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2009.04.020_bib19","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/jac\/dkn297","article-title":"Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efa-virenz","volume":"62","author":"Llibre","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2009.04.020_bib20","series-title":"Presented at: 3rd International AIDS Conference","article-title":"Substantial improvement of oral bioavailability of TMC125 using new tablet formulations in healthy volunteers","author":"Scholler","year":"2005"},{"key":"10.1016\/j.clinthera.2009.04.020_bib21","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/QAD.0b013e3282170ab1","article-title":"Pharmacokinetics and antiretro-viral response to darunavir\/ritonavir and etravirine combination in patients with high-level viral resistance","volume":"21","author":"Boffito","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.clinthera.2009.04.020_bib22","series-title":"Presented at: 15th Conference on Retroviruses and Opportunistic Infections","article-title":"Pharmacokinetics and pharma-codynamics of the NNRTI etravir-ine (ETR; TMC125) in treatment-experienced HIV-1-infected patients: Pooled 24-week results of DUET-1 and DUET-2","author":"Kakuda","year":"2008"},{"key":"10.1016\/j.clinthera.2009.04.020_bib23","series-title":"Presented at: 7th Annual Meeting of the American Association of Pharmaceutical Scientists","article-title":"Interspecies comparison of the in vitro metabolism of the anti-HIV compound TMC125","author":"Raaoof","year":"2006"},{"key":"10.1016\/j.clinthera.2009.04.020_bib24","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/14787210.6.4.427","article-title":"Etravirine for the treatment of HIV infection","volume":"6","author":"Seminari","year":"2008","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.clinthera.2009.04.020_bib25","series-title":"Presented at: 7th Annual Meeting of the American Association of Pharmaceutical Scientists","article-title":"In vivo metabolism and mass balance of the anti-HIV compound TMC125 in laboratory animals and healthy volunteers","author":"Raoof","year":"2006"},{"key":"10.1016\/j.clinthera.2009.04.020_bib26","series-title":"Presented at: 3rd International Workshop on Clinical Pharmacology of HIV Therapy","article-title":"Pharmacokinetics of TMC125 in HIV-infected patients and healthy volunteers","author":"Piscitelli","year":"2002"},{"key":"10.1016\/j.clinthera.2009.04.020_bib27","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1365-2125.2008.03214.x","article-title":"A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers","volume":"66","author":"Sch\u00f6ller-Gy\u00fcre","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2009.04.020_bib28","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1592\/phco.28.10.1215","article-title":"Effects of different meal compositions and fasted state on the oral bioavailability of etravirine","volume":"28","author":"Sch\u00f6ller-Gy\u00fcre","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2009.04.020_bib29","series-title":"Presented at: XVII International AIDS Conference","article-title":"Pharmacokinetics of etravirine are not affected by sex, age, race, treatment duration or use of enfuvirtide in HIV-1-infected subjects","author":"Kakuda","year":"2008"},{"key":"10.1016\/j.clinthera.2009.04.020_bib30","series-title":"Presented at: 14th Conference on Retroviruses and Opportunistic Infections","article-title":"Pharmacokinetics and pharmacodynamics ofTMC125 in HIV-infected patients with non-nucleoside reverse transcriptase inhibitor and protease inhibitor resistance: TMC125-C223","author":"Kakuda","year":"2007"},{"key":"10.1016\/j.clinthera.2009.04.020_bib31","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1097\/00002030-200311210-00011","article-title":"A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monothera-py in antiretroviral naive, HIV-1 infected subjects","volume":"17","author":"Gruzdev","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.clinthera.2009.04.020_bib32","doi-asserted-by":"crossref","first-page":"F49","DOI":"10.1097\/00002030-200312050-00001","article-title":"An open-label assessment of TMC 125-a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance","volume":"17","author":"Gazzard","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.clinthera.2009.04.020_bib33","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1086\/591705","article-title":"Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb doseranging study involving treatment-experienced patients with HIV-1 infection","volume":"47","author":"Montaner","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2009.04.020_bib34","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0b013e32805e8776","article-title":"Efficacy and safety of etra-virine (TMC125) in patients with highly resistant HIV-1: Primary 24- week analysis","volume":"21","author":"Nadler","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.clinthera.2009.04.020_bib35","series-title":"Presented at: 15th Conference on Retroviruses and Opportunistic Infections","article-title":"DUET-1: Week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus pla- cebo in 612 treatment-experienced HIV-1-infected patients","author":"Haubrich","year":"2008"},{"key":"10.1016\/j.clinthera.2009.04.020_bib36","series-title":"Presented at: 15th Conference on Retroviruses and Opportunistic Infections","article-title":"DUET-2: Week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETRl TMC125) versus placebo in 591 treatment-experienced HIV-1-infected patients","author":"Johnson","year":"2008"},{"key":"10.1016\/j.clinthera.2009.04.020_bib37","series-title":"Presented at: 45th Annual Meeting of the Infectious Diseases Society of America","article-title":"TMC125 safety and tol-erability in treatment-experienced, HIV infected patients-pooled DUET trial data","author":"Haubrich","year":"2007"},{"key":"10.1016\/j.clinthera.2009.04.020_bib38","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1345\/aph.1K681","article-title":"Etravirine has no effect on QT and corrected QT interval in HIVnegative volunteers","volume":"42","author":"Peeters","year":"2008","journal-title":"Ann Pharmaco- ther"},{"key":"10.1016\/j.clinthera.2009.04.020_bib39","series-title":"Presented at: 8th International Congress on Drug Therapy in HIV Infection","article-title":"TMC125 in combination with other medications: Summary of drug-drug interaction studies","author":"Kakuda","year":"2006"},{"key":"10.1016\/j.clinthera.2009.04.020_bib40","series-title":"Presented at: 8th International Congress on Drug Therapy in HIV Infection","article-title":"Pharmacokinetics of TMC125 with atazanavir and atazanavir\/ritonavir","author":"Sch\u00f6ller-Gy\u00fcre","year":"2006"},{"key":"10.1016\/j.clinthera.2009.04.020_bib41","series-title":"Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Drug interactions with TMC125, a potent next generation NNRTI","author":"Baede","year":"2002"},{"key":"10.1016\/j.clinthera.2009.04.020_bib42","series-title":"Presented at: 13th Conference on Retroviruses and Opportunistic Infections","article-title":"Significant decrease in TMC125 exposures when co-administered with tipranavir boosted with ritona-vir in healthy subjects","author":"Sch\u00f6ller","year":"2006"},{"key":"10.1016\/j.clinthera.2009.04.020_bib43","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/j.1875-9114.1998.tb03830.x","article-title":"Update: Clinically significant cytochrome P-450 drug interactions","volume":"18","author":"Michalets","year":"1998","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.clinthera.2009.04.020_bib44","series-title":"Presented at: XVII International AIDS Conference","article-title":"Bioavail-ability of the 100mg etravirine tablet dispersed in water and of the 25mg pediatric tablet formulation","author":"Sch\u00f6ller-Gy\u00fcre","year":"2008"},{"key":"10.1016\/j.clinthera.2009.04.020_bib45","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2165\/00019053-200119070-00001","article-title":"Highly active antiretroviral therapy: Pharmacoeconomic issues in the management of HIV infection","volume":"19","author":"Sendi","year":"2001","journal-title":"Pharmaco Economics."},{"key":"10.1016\/j.clinthera.2009.04.020_bib46","series-title":"Presented at: XVII International AIDS Conference","article-title":"Analysis of US costs of full virologic suppression for treatment-experienced, HIV- infected patients in the DUET trials","author":"Martin","year":"2008"},{"key":"10.1016\/j.clinthera.2009.04.020_bib47","series-title":"Presented at: XVII International AIDS Conference","article-title":"Impact of etravirine on hospitalizations and hospital-related costs: 48-Week findings from pooled DUET trials","author":"Gebo","year":"2008"},{"key":"10.1016\/j.clinthera.2009.04.020_bib48","series-title":"XVII International AIDS Conference","article-title":"High rate of viro-logic success with raltegravir plus etravirine and darunavir\/ritonavir in treatment-experienced patients with multidrug-resistant virus: Results of the ANRS 139 TRIO trial","author":"Yazdanpanah","year":"2008"},{"key":"10.1016\/j.clinthera.2009.04.020_bib49","series-title":"Presented at: XVII International AIDS Conference","article-title":"The impact of background regimen on virologic response to etravirine: Pooled 48-week analysis of DUET-1 and DUET-2","author":"Di Perri","year":"2008"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809001295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809001295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:03:54Z","timestamp":1684973034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809001295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0149291809001295"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.04.020","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}